Illumina ( ILMN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Illumina rose 43 cents (1%) to $43.46 on light volume. Throughout the day, 1.2 million shares of Illumina exchanged hands as compared to its average daily volume of three million shares. The stock ranged in a price between $42.27-$43.53 after having opened the day at $42.99 as compared to the previous trading day's close of $43.03. Other companies within the Drugs industry that increased today were: Rosetta Genomics ( ROSG), up 51.3%, Accelr8 Technology Corporation ( AXK), up 17.3%, ImmuCell Corporation ( ICCC), up 15.3%, and Biosante Pharmaceuticals ( BPAX), up 14.3%. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $5.36 billion and is part of the health care sector. The company has a P/E ratio of 66.4, above the average drugs industry P/E ratio of 65.4 and above the S&P 500 P/E ratio of 17.7. Shares are up 41.2% year to date as of the close of trading on Tuesday. Currently there are eight analysts that rate Illumina a buy, one analyst rates it a sell, and 10 rate it a hold. TheStreet Ratings rates Illumina as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and premium valuation.